Pharmaceuticals Korean listed companies

Grouped by the industry code each company registered with DART. Sorted by latest quarterly operating profit.

Companies185

Operating profit₩1.73tnlatest quarter, combined

Operating losses78

Average dividend yield2.0%61 payers

There are 185 KOSPI and KOSDAQ companies classified under pharmaceuticals. Combined operating profit for the latest reported quarter across 178 of them was ₩1.73tn; 78 posted an operating loss and 11 swung to a profit from a loss a year earlier. The largest by quarterly operating profit were Samsung Biologics, Celltrion and Hanmi Pharm. The median operating margin across the 165 with reported revenue was 2.8%. 61 paid a cash dividend, with an average reported yield of 2.0%.

Pharmaceuticals companies

Company	Latest quarter op. profit	Dividend yield	Articles 30d	Signals
Samsung Biologics KOSPI	₩586bn +23% YoY	–	380	Op. margin 20%+ Insider buying Insider selling Supply contract M&A / stake deal
Celltrion KOSPI	₩452bn +86% YoY	–	969	Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ Share pledge Major holder adding Insider buying Insider selling Buyback Clinical trial filing
Hanmi Pharm KOSPI	₩131bn +117% YoY	0.8%	657	Profit +50% Revenue & profit growth Op. margin 20%+ Share pledge Insider buying Clinical trial filing Dividend grower
Daewoong KOSPI	₩76.6bn -10% YoY	0.9%	38	–
Daewoong Pharma KOSPI	₩68.1bn +18% YoY	0.3%	369	Revenue & profit growth
Yuhan KOSPI	₩66.9bn +34% YoY	0.5%	487	Revenue & profit growth Insider buying Dividend grower
PharmaResearch KOSDAQ	₩66.5bn +19% YoY	0.9%	129	Revenue & profit growth Op. margin 20%+ Major holder adding Dividend grower
Hugel KOSDAQ	₩56.0bn -1% YoY	–	46	Op. margin 20%+
Oscotec KOSDAQ	₩38.7bn	–	43	Turnaround Revenue +30% Op. margin 20%+ Share pledge Stake purpose change Litigation
JW Pharmaceutical KOSPI	₩33.3bn +34% YoY	2.1%	184	Revenue & profit growth M&A / stake deal Dividend grower
HK inno.N KOSDAQ	₩30.0bn +54% YoY	0.8%	184	Profit +50% Major holder adding
Myungin Pharm KOSPI	₩27.6bn +10% YoY	2.1%	5	Op. margin 20%+ Dividend grower
DongKookPharmaceutical KOSDAQ	₩26.1bn +18% YoY	1.1%	252	Revenue & profit growth
T&L KOSDAQ	₩25.0bn +150% YoY	3.1%	1	Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ Dividend grower
Boryung KOSPI	₩23.8bn -6% YoY	1.7%	57	Treasury share sale M&A / stake deal
Seegene KOSDAQ	₩21.6bn +586% YoY	4.1%	42	Profit +50% Revenue & profit growth
Huons Global KOSDAQ	₩19.5bn -23% YoY	1.6%	4	–
Celltrion Pharm KOSDAQ	₩19.3bn +24% YoY	0.3%	6	Revenue & profit growth
Chong Kun Dang Pharmaceutical KOSPI	₩18.6bn -21% YoY	0.6%	122	Share pledge Insider selling Insider buying New 5% holder Major holder adding Dividend cut
ST Pharm KOSDAQ	₩18.3bn +42% YoY	0.3%	80	Revenue +30% Revenue & profit growth Share pledge Clinical trial filing
Korea United Pharm KOSPI	₩13.3bn +24% YoY	3.1%	47	Dividend grower
Humedix KOSDAQ	₩11.7bn +8% YoY	2.3%	123	Op. margin 20%+ Dividend grower
Dongwha Pharm KOSPI	₩10.3bn	1.0%	164	Dividend cut
KolmarBNH KOSDAQ	₩10.2bn -5% YoY	0.5%	23	Share pledge M&A / stake deal Dividend cut
JW Lifescience KOSPI	₩9.3bn -0% YoY	–	0	–
Ahn-gook Pharmaceutical KOSDAQ	₩8.6bn +74% YoY	7.0%	35	Profit +50% Revenue & profit growth High dividend Dividend grower
L&C Bio KOSDAQ	₩8.6bn	0.1%	147	Turnaround Revenue +30% Op. margin 20%+ Share pledge Insider buying Bonus issue
EuBiologics KOSDAQ	₩8.6bn -24% YoY	–	42	Op. margin 20%+ Clinical trial filing Supply contract
BioNote KOSPI	₩8.5bn +33% YoY	3.8%	0	Revenue & profit growth Op. margin 20%+
Boditech Med KOSDAQ	₩8.2bn -10% YoY	–	9	–
DaehanPharmaceutical KOSDAQ	₩8.1bn +4% YoY	3.3%	1	Insider buying Dividend grower
Whanin Pharm KOSPI	₩7.9bn +192% YoY	2.6%	2	Profit +50% Revenue & profit growth
Hana Pharm KOSPI	₩7.3bn +21% YoY	2.2%	3	Asset deal Dividend cut
Samjin Pharmaceutical KOSPI	₩7.2bn -10% YoY	3.9%	121	–
Chongkundang Holdings KOSPI	₩6.6bn -60% YoY	2.6%	3	Share pledge
Dong-a ST KOSPI	₩6.3bn	1.4%	108	Turnaround Clinical trial filing
High Tech Pharm KOSDAQ	₩6.3bn +96% YoY	–	2	Profit +50% Op. margin 20%+
Metabiomed KOSDAQ	₩6.3bn -20% YoY	2.1%	7	Op. margin 20%+ Insider buying Dividend grower
BioPlus KOSDAQ	₩6.2bn +202% YoY	1.4%	20	Profit +50% Revenue & profit growth Op. margin 20%+ Major holder adding
Hanall Biopharma KOSPI	₩5.6bn +389% YoY	–	85	Profit +50% Insider selling
Caregen KOSDAQ	₩5.2bn -30% YoY	0.7%	4	Op. margin 20%+ Insider buying Dividend cut
Medy-Tox KOSDAQ	₩4.8bn -25% YoY	1.0%	58	–
GC WellBeing KOSDAQ	₩4.6bn +10% YoY	1.5%	3	Revenue +30% Dividend grower
JIN Yang Pharmaceutical KOSDAQ	₩4.2bn +70% YoY	–	1	Profit +50%
Hans Biomed KOSDAQ	₩4.1bn	–	1	Revenue +30%
RPbio KOSDAQ	₩4.1bn +76% YoY	10.0%	5	Profit +50% Revenue & profit growth High dividend
Sinsin Pharmaceutical KOSDAQ	₩4.1bn +83% YoY	1.4%	2	Profit +50% Revenue & profit growth
Yuyu Pharma KOSPI	₩4.0bn +78% YoY	2.5%	73	Profit +50%
CTC Bio KOSDAQ	₩3.8bn +67% YoY	–	4	Profit +50% Litigation
KyungdongPharm KOSDAQ	₩3.7bn	4.9%	0	Insider buying Major holder adding
Daebongls KOSDAQ	₩3.7bn +56% YoY	0.6%	23	Profit +50% Revenue & profit growth
JW Shinyak KOSDAQ	₩3.6bn +34% YoY	–	3	–
Sewoonmedical KOSDAQ	₩3.4bn +41% YoY	–	0	Revenue & profit growth Share pledge
Sam Chun Dang Pharm KOSDAQ	₩3.4bn	0.0%	92	Turnaround Share pledge Supply contract Dividend cut
Dae Hwa Pharm KOSDAQ	₩3.3bn	–	34	Insider selling
Huons KOSDAQ	₩2.9bn -78% YoY	3.3%	96	–
Kwangdong Pharmaceutical KOSPI	₩2.8bn -38% YoY	1.1%	187	Major holder adding
Wonbiogen KOSDAQ	₩2.8bn +47% YoY	2.2%	3	Op. margin 20%+ Dividend grower
Handok KOSPI	₩2.8bn	1.8%	130	Share pledge
Korean Drug KOSDAQ	₩2.7bn +19% YoY	4.1%	4	Revenue & profit growth Dividend grower
Theragen Etex KOSDAQ	₩2.6bn	–	1	Turnaround Insider selling
OPTUS Pharmaceutical KOSDAQ	₩2.3bn -25% YoY	–	7	–
Jetema KOSDAQ	₩2.3bn +30% YoY	–	26	Share pledge Major holder adding Supply contract
Shinil Pharmaceutical KOSDAQ	₩2.3bn -29% YoY	3.0%	0	–
Korea Pharma KOSDAQ	₩2.2bn	–	5	Buyback
Daehan Nupharm KOSDAQ	₩2.2bn -30% YoY	1.4%	1	Share pledge
Kukje Pharma KOSPI	₩2.1bn -39% YoY	0.6%	67	Share pledge Insider selling Insider buying Control change
Bio-fd&c KOSDAQ	₩2.1bn +14% YoY	–	2	Op. margin 20%+ Share pledge
Aminologics KOSDAQ	₩2.0bn	–	0	Op. margin 20%+ Insider selling
IL Dong Pharmaceutical KOSPI	₩2.0bn	0.6%	78	M&A / stake deal
DuChemBio KOSDAQ	₩1.9bn +2% YoY	–	26	–
Ildong Holdings KOSPI	₩1.9bn	0.9%	0	Turnaround
Sam-A Pharm KOSDAQ	₩1.9bn -7% YoY	–	0	–
Green Lifescience KOSDAQ	₩1.8bn	–	0	Revenue +30%
PharmGen Science KOSPI	₩1.8bn -46% YoY	–	17	–
GC Biopharma KOSPI	₩1.7bn -94% YoY	–	329	–
Cell Biotech KOSDAQ	₩1.6bn +28% YoY	4.4%	20	Revenue +30% Revenue & profit growth
Komipharm International KOSDAQ	₩1.6bn +1% YoY	–	6	Insider buying
Cellumed KOSDAQ	₩1.6bn	–	0	Turnaround
Kukjeon KOSDAQ	₩1.5bn	–	3	Turnaround Share pledge Dilution risk Dividend cut
Bukwang Pharmaceutical IND KOSPI	₩1.4bn -30% YoY	3.3%	137	Revenue +30%
WooGeneB&G KOSDAQ	₩1.4bn	–	1	–
Bioneer KOSDAQ	₩1.2bn -78% YoY	–	1	Insider buying
Choong Ang Vaccine Laboratory KOSDAQ	₩1.1bn -24% YoY	–	0	–
Withus Pharmaceutical KOSDAQ	₩1.1bn	–	2	–
Tdspharm KOSDAQ	₩1.0bn	–	4	–
HLB Genex KOSDAQ	₩959m -33% YoY	–	17	Major holder adding
Kyongbo Pharmaceutical KOSPI	₩930m -61% YoY	–	2	–
Polaris AI Pharma KOSDAQ	₩779m -39% YoY	–	0	–
Samyang Biopharm KOSPI	₩746m	–	29	–
GC Medical Science KOSDAQ	₩743m -30% YoY	–	5	Insider buying
ISU Abxis KOSDAQ	₩479m -95% YoY	–	0	–
SCL Science KOSDAQ	₩406m	–	21	Turnaround M&A / stake deal
Cheil Bio KOSDAQ	₩343m	–	0	Turnaround
SunBio KOSDAQ	₩284m	–	0	–
MFC KOSDAQ	₩239m	–	3	–
Bcworldpharm KOSDAQ	₩147m -92% YoY	1.8%	3	–
Nibec KOSDAQ	₩103m -99% YoY	–	16	–
Orientbio KOSPI	₩50m	–	4	Turnaround
DongKook Life Science KOSDAQ	₩22m -99% YoY	–	31	–
Kolon TissueGene KOSDAQ	−₩5m	–	13	Litigation 4 quarters of losses
Daewon Pharmaceutical KOSPI	−₩9m	–	200	Clinical trial filing
Access Bio KOSDAQ	−₩16m	–	8	Supply contract 4 quarters of losses
ChoA Pharmaceutical KOSDAQ	−₩23m	–	13	4 quarters of losses
Olipass KOSDAQ	−₩117m	–	2	Delisting / halt risk 4 quarters of losses
NKGen Biotech Korea KOSDAQ	−₩130m	–	8	–
HLB Panagene KOSDAQ	−₩158m	–	15	4 quarters of losses
Optipharm KOSDAQ	−₩206m	–	7	4 quarters of losses
Kyung Nam Pharm KOSDAQ	−₩212m	–	19	–
Pangen Biotech KOSDAQ	−₩220m	–	1	Swung to loss
Samik Pharm KOSDAQ	−₩228m -120% YoY	0.3%	8	Swung to loss Asset deal
Seoul Pharma KOSDAQ	−₩343m	–	2	4 quarters of losses
BNC Korea KOSDAQ	−₩366m -123% YoY	1.5%	14	Swung to loss Share pledge 4 quarters of losses
Celestra KOSDAQ	−₩447m	–	0	4 quarters of losses
Daesung Microbiological Labs KOSDAQ	−₩472m	1.0%	0	Swung to loss
Bio Solution KOSDAQ	−₩482m	–	23	4 quarters of losses
Hass KOSDAQ	−₩615m	0.8%	3	Swung to loss Dividend cut
Naturecell KOSDAQ	−₩702m	–	9	4 quarters of losses
Gencurix KOSDAQ	−₩702m	–	7	Delisting / halt risk M&A / stake deal 4 quarters of losses
PeopleBio KOSDAQ	−₩749m	–	0	Share pledge Split / consolidation 4 quarters of losses
Kolon Life Science KOSDAQ	−₩785m -162% YoY	–	29	Swung to loss
Telcon RF Pharmaceutical KOSDAQ	−₩806m	–	4	Revenue +30% Supply contract
Myungmoon Pharm KOSPI	−₩836m -115% YoY	–	0	Swung to loss Insider buying
Asta KOSDAQ	−₩839m	–	16	Swung to loss Control change Supply contract Litigation 4 quarters of losses
Hwail Pharm KOSDAQ	−₩912m	–	1	Swung to loss Dilution risk Private placement Control change
Celemics KOSDAQ	−₩924m	–	3	4 quarters of losses
T&R Biofab KOSDAQ	−₩928m	–	15	4 quarters of losses
Tego Science KOSDAQ	−₩1.2bn	–	0	4 quarters of losses
Union Korea Pharm KOSDAQ	−₩1.3bn	–	31	Dilution risk Private placement Capital reduction 4 quarters of losses
HLB Pep KOSDAQ	−₩1.4bn	–	12	Asset deal 4 quarters of losses
Yungjin Pharm KOSPI	−₩1.5bn -179% YoY	–	14	Swung to loss Supply contract
Ilsung IS KOSPI	−₩1.6bn	5.4%	0	High dividend 4 quarters of losses
Genolution KOSDAQ	−₩1.6bn	–	26	Insider buying Major holder adding 4 quarters of losses
iNtRON Biotechnology KOSDAQ	−₩1.6bn	–	11	4 quarters of losses
Adbiotech KOSDAQ	−₩1.9bn	–	9	–
Vivozon Pharmaceutical KOSDAQ	−₩1.9bn	–	1	Share pledge 4 quarters of losses
Dongsung Pharmaceutical KOSPI	−₩2.0bn	–	10	Litigation
Eutilex KOSDAQ	−₩2.2bn	–	0	4 quarters of losses
QuadMedicine KOSDAQ	−₩2.4bn	–	6	Swung to loss Insider buying Clinical trial filing
Keeps Biopharma KOSDAQ	−₩2.4bn	–	5	Revenue +30% Insider buying Share pledge Clinical trial filing
Cellbion KOSDAQ	−₩2.6bn	–	8	Clinical trial filing 4 quarters of losses
G2gbio KOSDAQ	−₩2.7bn	–	79	4 quarters of losses
Xcell Therapeutics KOSDAQ	−₩2.8bn	–	0	Insider buying 4 quarters of losses
It-chem KOSDAQ	−₩2.8bn	–	0	–
CMG Pharmaceutical KOSDAQ	−₩3.0bn	–	23	Insider selling Delisting / halt risk
Shaperon KOSDAQ	−₩3.1bn	–	39	Insider selling Clinical trial filing Delisting / halt risk 4 quarters of losses
FutureChem KOSDAQ	−₩3.2bn	–	17	Clinical trial filing 4 quarters of losses
Humasis KOSDAQ	−₩3.3bn	–	9	4 quarters of losses
S.Biomedics KOSDAQ	−₩3.7bn	–	0	4 quarters of losses
Enzychem Lifesciences KOSDAQ	−₩4.1bn	–	6	Revenue +30% Share pledge Litigation 4 quarters of losses
Sugentech KOSDAQ	−₩4.2bn	–	2	4 quarters of losses
Corestemchemon KOSDAQ	−₩4.3bn	–	8	4 quarters of losses
Korea Arlico Pharm KOSDAQ	−₩4.6bn -375% YoY	1.7%	2	Swung to loss Insider buying
ENCell KOSDAQ	−₩4.7bn	–	17	4 quarters of losses
Samsung Pharmaceutical KOSPI	−₩5.0bn	–	1	Clinical trial filing 4 quarters of losses
CKD Bio KOSPI	−₩5.0bn -274% YoY	–	5	Swung to loss Dividend cut
Kangstem Biotech KOSDAQ	−₩6.1bn	–	15	Clinical trial filing 4 quarters of losses
AbClon KOSDAQ	−₩6.3bn	–	24	Supply contract Clinical trial filing 4 quarters of losses
Samil Pharmaceutical KOSPI	−₩6.3bn	–	20	Share pledge Insider buying 4 quarters of losses
DongKoo Bio & Pharma KOSDAQ	−₩6.5bn -434% YoY	–	31	Swung to loss Share pledge
Ilyang Pharmaceutical KOSPI	−₩6.8bn -678% YoY	1.2%	13	Swung to loss
Reyon Pharmaceutical KOSPI	−₩7.0bn	–	6	Share pledge New 5% holder Major holder adding Dilution risk 4 quarters of losses
Jeil Pharmaceutical KOSPI	−₩7.0bn -250% YoY	–	71	Swung to loss
HLB Life Science KOSDAQ	−₩7.6bn	–	3	4 quarters of losses
Peptron KOSDAQ	−₩7.9bn	–	100	4 quarters of losses
Genome&Company KOSDAQ	−₩8.0bn	–	38	4 quarters of losses
Shinpoong Pharmaceutical KOSPI	−₩8.0bn -263% YoY	–	11	Swung to loss Clinical trial filing
Binex KOSDAQ	−₩9.2bn -995% YoY	–	10	Swung to loss Share pledge
GeneOne Life Science KOSPI	−₩12.8bn	–	15	Litigation 4 quarters of losses
Rokit Healthcare KOSDAQ	−₩13.5bn	–	79	Swung to loss
Orum Therapeutics KOSDAQ	−₩15.4bn	–	25	Insider buying 4 quarters of losses
SK Bioscience KOSPI	−₩15.7bn	–	90	4 quarters of losses
ABL Bio KOSDAQ	−₩16.8bn -141% YoY	–	66	Swung to loss Share pledge 4 quarters of losses
Aprogen Biologics KOSPI	−₩17.5bn	–	0	Revenue +30% Share pledge Major holder adding Insider buying 4 quarters of losses
Aprogen KOSPI	−₩22.4bn	–	0	Revenue +30% Major holder adding M&A / stake deal 4 quarters of losses
HLB KOSDAQ	−₩22.5bn	–	313	Revenue +30% 4 quarters of losses
Medipost KOSDAQ	−₩24.3bn	–	25	M&A / stake deal 4 quarters of losses
Chabiotech KOSDAQ	−₩28.2bn	–	1	Share pledge 4 quarters of losses
Hyundai Pharmaceutical KOSPI	–	0.3%	55	–
Poongjeon Pharmacy KOSDAQ	–	–	5	Dilution risk Private placement 4 quarters of losses
Prestige Biologics KOSDAQ	–	–	5	Split / consolidation 4 quarters of losses
Pharmaresearch Bio KONEX	–	–	3	Insider selling
PCL KOSDAQ	–	–	3	–
BASKHANBIOPharma KONEX	–	–	0	–
Imgt KONEX	–	–	0	–

Industry codes are the primary business each company registered with DART and may not reflect its full business mix. Figures come from DART filings; prices are not included. Not investment advice.